Importation, Pricing Policies Raised Concerns For US FDA's Project Orbis

Allowing multi-regulator collaboration on oncology application assessment may run into pricing issues if Canada and Australia gain access to novel drugs before European countries, US FDA's Pazdur says.

Global strategy solution concept - earth jigsaw puzzle
Singapore and Switzerland could join Project Orbis soon. • Source: Shutterstock

Richard Pazdur worried that his program allowing simultaneous submission and assessment of drug applications in the US and other countries would be improperly linked to, and potentially damaged by, White House plans to allow drug importation from Canada.

The director of the US Food and Drug Administration's Oncology Center of Excellence also was concerned that ex-US drug pricing...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pricing Debate

More from Market Access